The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis.
ERG
Endothelial cells
FLI1
IL-6
OSM
OSMRβ
SSc
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
31 07 2020
31 07 2020
Historique:
received:
08
04
2020
accepted:
09
07
2020
entrez:
2
8
2020
pubmed:
2
8
2020
medline:
22
6
2021
Statut:
epublish
Résumé
Scleroderma (SSc) is a rare autoimmune disease characterized by vascular impairment and progressive fibrosis of the skin and other organs. Oncostatin M, a member of the IL-6 family, is elevated in SSc serum and was recognized as a significant player in various stages of fibrosis. The goal of this study was to assess the contribution of the OSM/OSMRβ pathway to endothelial cell (EC) injury and activation in SSc. IHC and IF were used to assess the distribution of OSM and OSMRβ in SSc (n = 14) and healthy control (n = 7) skin biopsies. Cell culture experiments were performed in human dermal microvascular endothelial cells (HDMECs) and included mRNA and protein analysis, and cell migration and proliferation assays. Ex vivo skin organoid culture was used to evaluate the effect of OSM on perivascular fibrosis. OSMRβ protein was elevated in dermal ECs and in fibroblasts of SSc patients. Treatments of HDMECs with OSM or IL-6+sIL-6R have demonstrated that both cytokines similarly stimulated proinflammatory genes and genes related to endothelial to mesenchymal transition (EndMT). OSM was more effective than IL-6+sIL-6R in inducing cell migration, while both treatments similarly induced cell proliferation. The effects of OSM were mediated via OSMRβ and STAT3, while the LIFR did not contribute to these responses. Both OSM and IL-6+sIL-6R induced profibrotic gene expression in HDMECs, as well as expansion of the perivascular PDGFRβ This work provides new insights into the role of the OSM/OSMRβ axis in activation/injury of dermal ECs and supports the involvement of this pathway in SSc vascular disease.
Sections du résumé
BACKGROUND
Scleroderma (SSc) is a rare autoimmune disease characterized by vascular impairment and progressive fibrosis of the skin and other organs. Oncostatin M, a member of the IL-6 family, is elevated in SSc serum and was recognized as a significant player in various stages of fibrosis. The goal of this study was to assess the contribution of the OSM/OSMRβ pathway to endothelial cell (EC) injury and activation in SSc.
METHODS
IHC and IF were used to assess the distribution of OSM and OSMRβ in SSc (n = 14) and healthy control (n = 7) skin biopsies. Cell culture experiments were performed in human dermal microvascular endothelial cells (HDMECs) and included mRNA and protein analysis, and cell migration and proliferation assays. Ex vivo skin organoid culture was used to evaluate the effect of OSM on perivascular fibrosis.
RESULTS
OSMRβ protein was elevated in dermal ECs and in fibroblasts of SSc patients. Treatments of HDMECs with OSM or IL-6+sIL-6R have demonstrated that both cytokines similarly stimulated proinflammatory genes and genes related to endothelial to mesenchymal transition (EndMT). OSM was more effective than IL-6+sIL-6R in inducing cell migration, while both treatments similarly induced cell proliferation. The effects of OSM were mediated via OSMRβ and STAT3, while the LIFR did not contribute to these responses. Both OSM and IL-6+sIL-6R induced profibrotic gene expression in HDMECs, as well as expansion of the perivascular PDGFRβ
CONCLUSIONS
This work provides new insights into the role of the OSM/OSMRβ axis in activation/injury of dermal ECs and supports the involvement of this pathway in SSc vascular disease.
Identifiants
pubmed: 32736577
doi: 10.1186/s13075-020-02266-0
pii: 10.1186/s13075-020-02266-0
pmc: PMC7393919
doi:
Substances chimiques
OSM protein, human
0
Oncostatin M Receptor beta Subunit
0
Oncostatin M
106956-32-5
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
179Subventions
Organisme : NIAMS NIH HHS
ID : AR44883
Pays : United States
Références
Lancet. 2016 Jun 25;387(10038):2630-2640
pubmed: 27156934
Sci Rep. 2016 Oct 14;6:35282
pubmed: 27739482
Circ Res. 2009 May 8;104(9):1049-57
pubmed: 19359602
Ann Rheum Dis. 2017 May;76(5):924-934
pubmed: 28062404
Rheumatology (Oxford). 1999 Jul;38(7):612-7
pubmed: 10461473
J Immunol. 2008 Nov 15;181(10):7243-53
pubmed: 18981146
Pharmacol Res. 2016 Jun;108:46-56
pubmed: 27073018
J Immunol. 2012 Sep 1;189(5):2635-44
pubmed: 22826322
Am J Respir Cell Mol Biol. 2017 Jul;57(1):121-131
pubmed: 28248553
Scand J Rheumatol. 2005 Jul-Aug;34(4):293-7
pubmed: 16195162
J Cell Commun Signal. 2013 Jun;7(2):103-8
pubmed: 23255051
PLoS Genet. 2018 Nov 30;14(11):e1007826
pubmed: 30500808
J Exp Med. 1996 Jul 1;184(1):81-92
pubmed: 8691152
Int J Mol Sci. 2017 Nov 29;18(12):
pubmed: 29186034
Connect Tissue Res. 2019 Jan;60(1):40-49
pubmed: 30056769
Methods Mol Med. 1999;18:261-9
pubmed: 21370183
Front Immunol. 2018 Feb 20;9:294
pubmed: 29515588
Sci Transl Med. 2018 Jan 31;10(426):
pubmed: 29386358
J Clin Med. 2016 Apr 11;5(4):
pubmed: 27077889
FASEB J. 2016 Jan;30(1):129-40
pubmed: 26324850
Oncogene. 2017 Sep 28;36(39):5445-5459
pubmed: 28534515
J Vis Exp. 2015 Apr 18;(98):
pubmed: 25938583
J Cell Sci. 1997 Apr;110 ( Pt 7):871-9
pubmed: 9133674
Cells. 2019 Feb 05;8(2):
pubmed: 30764496
Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):45-49
pubmed: 30277866
J Exp Med. 2011 Jul 4;208(7):1459-71
pubmed: 21708929
Trends Immunol. 2012 Nov;33(11):571-7
pubmed: 22883707
Trends Cardiovasc Med. 2013 Jul;23(5):135-42
pubmed: 23295082
J Biol Chem. 2001 Dec 14;276(50):47038-45
pubmed: 11602599
J Rheumatol. 1998 Feb;25(2):308-13
pubmed: 9489824
Nat Rev Immunol. 2007 Oct;7(10):803-15
pubmed: 17893694
J Neuropathol Exp Neurol. 2001 Nov;60(11):1087-98
pubmed: 11706938
Arthritis Rheumatol. 2015 May;67(5):1335-44
pubmed: 25707716
Curr Rheumatol Rep. 2013 Feb;15(2):304
pubmed: 23307576
J Cell Physiol. 2013 Aug;228(8):1774-83
pubmed: 23359533
Nat Commun. 2017 Oct 24;8(1):1130
pubmed: 29066712
Basic Res Cardiol. 2014 Jan;109(1):396
pubmed: 24292852
J Immunol. 2018 Jan 1;200(1):248-259
pubmed: 29141862
Ann Rheum Dis. 2018 Sep;77(9):1362-1371
pubmed: 29853453
Cytokine Growth Factor Rev. 2012 Jun;23(3):99-107
pubmed: 22561547
BBA Clin. 2014 Jan 08;1:2-11
pubmed: 26675476
Hepatology. 2018 Jan;67(1):296-312
pubmed: 28779552
Am J Respir Cell Mol Biol. 2008 May;38(5):566-71
pubmed: 18096870
Proc Natl Acad Sci U S A. 2013 Oct 15;110(42):16975-80
pubmed: 24082147
Ann Rheum Dis. 2014 Jun;73(6):1232-9
pubmed: 23698475
Am J Pathol. 2010 Apr;176(4):1983-98
pubmed: 20228226
Cold Spring Harb Perspect Biol. 2018 Feb 1;10(2):
pubmed: 28620096
N Engl J Med. 2014 Jan 30;370(5):433-43
pubmed: 24350901
Cardiovasc Res. 2012 Apr 1;94(1):125-35
pubmed: 22287577
Dev Dyn. 2018 Mar;247(3):492-508
pubmed: 28891150
Nat Rev Drug Discov. 2017 Dec;16(12):843-862
pubmed: 29104284
Int J Mol Sci. 2018 Aug 05;19(8):
pubmed: 30081609
Lab Invest. 2014 Sep;94(9):1003-16
pubmed: 24933422
Am J Pathol. 2012 Jan;180(1):165-76
pubmed: 22062222
Cell Signal. 2018 Apr;44:118-126
pubmed: 29339086
Arthritis Rheumatol. 2018 Jun;70(6):912-919
pubmed: 29858547
Atherosclerosis. 2012 Oct;224(2):309-17
pubmed: 22673743